Background: SARS CoV2 is a newly emerged animal beta coronavirus that causes respiratory
illness. This infection has affected 212 countries to date and has been declared a pandemic by the
World Health Organization. Due to the high transmission rate and lack of availability of any approved
anti-viral drug, the formulation of a specific anti-viral therapy has now become a global emergency. Genomic
studies have revealed a 79% identity of SARS CoV2 with SARS CoV and 50% identity with
MERS CoV, which has given a clue point to test the drugs that were efficient against previously encountered
beta coronaviruses. For this purpose, several clinical trials based on the knowledge of existing
drugs are moving ahead. These therapies include chloroquine and hydroxychloroquine, remdesivir, corticosteroids
therapy, favipiravir, ribavirin, lopinavir/ritonavir, anti-cytokine therapy, and convalescent
Aim of the study: The purpose of this review is to give a pointer of contributions conducted globally,
including strategies utilized for treatments, the pattern of dosage, adverse reactions, and effective outcomes
from different drugs.
Methodology: Literature has been retrieved from PubMed, PubMed Central, ResearchGate, ScienceDirect,
and Google Scholar, using a combination of keywords for extensive information.
Conclusion: Among all the drug options, Remdesivir and the use of Convalescent Sera have been considered
as the safest options for treatment against COVID-19. Data from the ongoing clinical trials will
be required for the formulation of a specific and approved anti-viral drug.